2025-05-14
1. Summary of the Week
In the first week of May, a total of 15 agreements were signed globally. Within the China biotech sector, the activity included two out-licensing deals, one in-licensing deal, and one domestic partnership.
Formosa Pharmaceuticals entered an out-licensing agreement with Apotex for its approved asset, APP13007. Additionally, Almac Discovery signed an in-licensing agreement with Formosa Pharmaceuticals for the pre-clinical asset ALM-401. Tenacia Biotechnology and TSH Biopharma signed a domestic deal for the approved asset, ganaxolone.
Globally, 11 deals were publicly announced. The most significant deal of the week was between Alchemab Therapeutics and Eli Lilly on ATLX-1282, valued at $415m.
2025年5月1-9日，全球医药市场共签署了15项资产授权和合作协议。中国市场共达成4项交易，包括2项出海交易、1项引进交易和1项国内交易。
国内交易包括台新药向Apotex授权一款已上市资产APP13007；台新药从Almac Discovery引进一款临床前资产ALM-401；原启生物与Umoja Biopharma达成战略合作，携手开发创新型体内CAR-T；元羿生物与东生华制药达成战略合作，推动已获批资产加奈索酮在中国台湾地区的商业化。
国际市场上，本周共签署了11项资产授权和合作协议。最值得关注的一项交易是AlchemabTherapeutics 与Eli Lilly就临床前资产ATLX-1282达成的授权交易，总价值4.15亿美元。
2. Licensing Deals
2a. China Section
2b. Global Section
3. M&A Deals
4. Top Deals of 2025
4. 2019-2024 China Innovative Drug Licensing Transactions
About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai-based boutique investment and advisory firm, with a professional team in our China, U.S., EU, and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong, proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross-border licensing transactions. For more information, please visit http://www.yafocapital.com
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一。
ACCESS CHINA
Event Name:
2025-06-15 ACCESS CHINA BD Forum @BIO, Virtual & Boston
BioToChina.org 